Generation Bio’s (GBIO) Buy Rating Reiterated at Canaccord Genuity Group

Generation Bio (NASDAQ:GBIO)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity Group in a report released on Monday,Benzinga reports. They presently have a $9.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Generation Bio in a report on Friday.

Generation Bio Stock Performance

Shares of GBIO stock traded up $0.00 during mid-day trading on Monday, reaching $0.48. 207,252 shares of the company were exchanged, compared to its average volume of 244,617. The company has a market capitalization of $32.33 million, a P/E ratio of -0.22 and a beta of 2.72. The business’s 50 day simple moving average is $0.74 and its 200 day simple moving average is $1.51. Generation Bio has a fifty-two week low of $0.47 and a fifty-two week high of $4.65.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The business had revenue of $4.19 million during the quarter, compared to analyst estimates of $2.92 million. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. On average, analysts forecast that Generation Bio will post -1.75 EPS for the current year.

Insider Activity at Generation Bio

In other Generation Bio news, Director Anthony G. Quinn purchased 85,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $0.97 per share, for a total transaction of $82,450.00. Following the completion of the transaction, the director now owns 299,286 shares in the company, valued at $290,307.42. The trade was a 39.67 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 21.10% of the company’s stock.

Institutional Trading of Generation Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Aegis Wealth Management LLC acquired a new stake in Generation Bio during the 4th quarter worth about $94,000. Jefferies Financial Group Inc. acquired a new stake in Generation Bio during the 4th quarter worth about $2,398,000. Squarepoint Ops LLC acquired a new stake in Generation Bio during the 4th quarter worth about $70,000. Millennium Management LLC acquired a new stake in Generation Bio during the 4th quarter worth about $97,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Generation Bio by 13.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 311,535 shares of the company’s stock worth $330,000 after buying an additional 38,090 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.